EichorEICHOR
Condition: Avutometinib Synced from ClinicalTrials.gov · August 05, 2026

Recruiting studies: Avutometinib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung
Phase 2 · 3 location(s) · Emory University · NCT06495125A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06394804Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutan
Phase 1/Phase 2 · 2 location(s) · University of Utah · NCT06194929A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05787561A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06007924VS-6766+Abema+Fulv in Met HR+/HER- BC
Phase 1/Phase 2 · 3 location(s) · Adrienne G. Waks · NCT05608252Avutometinib and Defactinib in Diffuse Gastric Cancer
Phase 2 · 1 location(s) · Ryan H. Moy, MD, PhD · NCT06487221Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT063692595G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Phase 1/Phase 2 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06630260A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Phase 2 · 4 location(s) · University of Oklahoma · NCT05512208Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT07318324A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Phase 3 · 106 location(s) · Verastem, Inc. · NCT06072781
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.